# A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

> **NCT02556463** · PHASE1 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 53 (actual)

## Conditions studied

- Solid Tumors
- CTCL
- Cancer

## Interventions

- **DRUG:** MEDI9197
- **BIOLOGICAL:** durvalumab

## Key facts

- **NCT ID:** NCT02556463
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-04
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-10-26
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Company strategy
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556463, "A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02556463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*